Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test
Several years after its US approval, Ultragenyx's therapy for long-chain fatty acid oxidation disorders, Dojolvi, has been greenlit in the UK.
Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.
Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.
Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.
Editor's Picks
